The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q2 2018 call → NOWe need to determine if management conveys that the reported results do not represent the business they are actually running today. The transcript shows management discussing Q2 2018 results. They mention that they are on track, with growth in clinics, patients, treatments. They discuss various items like Calcimimetics transition, Care Coordination margin improvement, divestment of Sound, and the ESRD PPS draft rule. They also discuss guidance for the year. Key points: Management says "We're on track to achieve our 2018 targets. Q2 is a good quarter and is an improvement from Q1 and we continue to see progress quarter-to-quarter and we will continue that through the back half of the year." This suggests they are progressing, but not necessarily that the reported period is stale relative to the operating present. They mention that the results are impacted by currency headwinds, but that's a normal factor. They discuss the Calcimimetics transition: "we're probably two quarters in to two to four quarter process in order to get this sorted out" - this indicates an ongoing process, but not that the reported period is behind the current business. They also mention the divestment of Sound, which is a completed transaction, but that's a one-time event. They talk about the ESRD PPS draft rule for 2019, which is future. They mention that they expect to accelerate growth in the second half, but that's guidance, not a statement that the reported period is stale. They also discuss the next stage closing, which is pending. Overall, the call seems like a standard results and outlook discussion. Management is not indicating that the reported numbers describe a company that has been left behind. They are confirming guidance and discussing ongoing operations. There is no strong indication that the business as it stands today is ahead of the business as it appears in the reported period. They are not drawing attention to a gap between the print and current operations. They are just reporting results and outlook. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.